NLSP News & Events

NLS Pharmaceutics announced that it intends to effect a reverse share split of the company's issued and outstanding common shares, par value CHF 0.03 per share, at a ratio of 1-for-10. The company's common shares are expected to begin trading on the Nasdaq Capital Market on a post-split basis at the market open on October 31, under the new trading symbol (NCEL), and new name, NewcelX, following the anticipated closing of the merger with Kadimastem.

NLS Pharmaceutics (NLSP) and Kadimastem, a clinical-stage biotechnology company developing breakthrough cell therapy solutions for severe diseases such as ALS and diabetes, announced the signing of a Memorandum of Understanding between Kadimastem and TargetGene Biotechnologies, which deals in precision gene-editing technologies. This collaboration brings together Kadimastem's proprietary cell therapy platforms with TargetGene's DNA-guided gene-editing platform, enabling highly specific, multiplexed genome modifications with minimal off-target activity. The collaboration is expected to continue under the combined company, NewCelX, upon completion of the anticipated merger between NLS and Kadimastem. Pursuant to the MOU, the companies will jointly develop and optimize gene-edited cell therapy products. The MOU establishes a framework for joint R&D activities, technology exchange, and future licensing opportunities.

NLS Pharmaceutics and Kadimastem announced an update regarding the proposed merger. On October 21, NLS received an approval letter from the Nasdaq Listing Center for the listing of its common shares and the trading of the company on the Nasdaq Capital Market after completion of the Merger, under NLS's new name, NewcelX Ltd., with its new trading symbol for its common shares, (NCEL). Accordingly, the closing of the merger is expected to close on October 30 with the transition to trading under the combined company's new name beginning October 31, subject to fulfillment of the remaining customary closing conditions.

NLS Pharmaceutics' merger partner Kadimastem has been granted a patent by the Hong Kong Intellectual Property Department covering Kadimastem's proprietary cell selection and enrichment technology used in the development of IsletRx, a stem cell-derived therapy candidate intended to treat-and potentially cure-insulin-dependent diabetes. According to Kadimastem, the Hong Kong patent adds to previously granted patents in Europe, the United States and India, further strengthening the global protection around IsletRx. The patented process enables the selection and enrichment of highly functional islet cells from differentiated cell populations to help maximize therapeutic effect.